The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials
The orally administered spherical carbon adsorbent AST-120 is used on-label in Asian countries to slow renal disease progression in patients with progressive chronic kidney disease (CKD). Recently, two multinational, randomized, double-blind, placebo-controlled, phase 3 trials (Evaluating Prevention...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
30 September 2016
|
| In: |
BMC nephrology
Year: 2016, Jahrgang: 17, Pages: 1-8 |
| ISSN: | 1471-2369 |
| DOI: | 10.1186/s12882-016-0357-9 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12882-016-0357-9 Verlag, lizenzpflichtig, Volltext: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-016-0357-9 
|
| Verfasserangaben: | Gerald Schulman, Tomas Berl, Gerald J. Beck, Giuseppe Remuzzi, Eberhard Ritz, Miho Shimizu, Yuko Shobu and Mami Kikuchi |
| Zusammenfassung: | The orally administered spherical carbon adsorbent AST-120 is used on-label in Asian countries to slow renal disease progression in patients with progressive chronic kidney disease (CKD). Recently, two multinational, randomized, double-blind, placebo-controlled, phase 3 trials (Evaluating Prevention of Progression in Chronic Kidney Disease [EPPIC] trials) examined AST-120’s efficacy in slowing CKD progression. This study assessed the efficacy of AST-120 in the subgroup of patients from the United States of America (USA) in the EPPIC trials. |
|---|---|
| Beschreibung: | Gesehen am 26.05.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1471-2369 |
| DOI: | 10.1186/s12882-016-0357-9 |